Anika Therapeutics (ANIK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Sales | 29,612 | 30,615 | 27,817 | 28,219 | 26,168 |
| Cost of Goods | 10,615 | 11,436 | 12,233 | 13,856 | 11,487 |
| Gross Profit | 18,997 | 19,179 | 15,584 | 14,363 | 14,681 |
| Operating Expenses | 25,100 | 18,969 | 19,050 | 19,399 | 19,452 |
| Operating Income | -5,488 | 646 | -3,233 | -4,180 | -4,284 |
| Other Income | 667 | 118 | 997 | 214 | 415 |
| Pre-tax Income | -4,821 | 764 | -2,236 | -3,966 | -3,869 |
| Income Tax | 235 | -1,037 | 939 | 681 | 89 |
| Net Income Continuous | -5,056 | 1,801 | -3,175 | -4,647 | -3,958 |
| Net Income Discontinuous | N/A | -1,509 | 846 | 677 | -915 |
| Net Income | $-5,056 | $292 | $-2,329 | $-3,970 | $-4,873 |
| EPS Basic Total Ops | -0.37 | 0.02 | -0.16 | -0.28 | -0.34 |
| EPS Basic Continuous Ops | -0.37 | 0.13 | -0.22 | -0.33 | -0.28 |
| EPS Basic Discontinuous Ops | N/A | -0.11 | 0.06 | 0.05 | -0.06 |
| EPS Diluted Total Ops | -0.37 | 0.02 | -0.16 | -0.28 | -0.34 |
| EPS Diluted Continuous Ops | -0.37 | 0.13 | -0.22 | -0.33 | -0.28 |
| EPS Diluted Discontinuous Ops | N/A | -0.11 | 0.06 | 0.05 | -0.06 |
| EPS Diluted Before Non-Recurring Items | -0.24 | 0.13 | -0.17 | -0.33 | -0.28 |
| EBITDA(a) | $-4,081 | $1,964 | $-1,830 | $-2,764 | $-2,692 |